NOV 17, 202649 MINS READ
The creatine phosphate molecule (N-phosphocreatine, CrP) serves as the immediate phosphoryl donor in the reversible reaction catalyzed by creatine kinase: CrP + ADP ⇌ Cr + ATP 5 6. Structurally, CrP comprises a guanidinium moiety covalently bonded to a phosphate group via a high-energy phosphorus-nitrogen (P-N) bond, which exhibits a standard free energy of hydrolysis (ΔG°') of approximately −43.0 kJ/mol under physiological conditions 1 2. This thermodynamic property positions CrP as a critical temporal energy buffer, enabling rapid ATP replenishment during transient metabolic surges 5 6.
Metabolomic investigations frequently employ creatine phosphate analogs to probe enzyme kinetics and pathway flux:
Quantitative metabolomic platforms (LC-MS/MS, GC-MS) routinely measure CrP, Cr, and analogs with detection limits in the low micromolar range (0.5–2 μM in serum; 5–30 mM in tissue extracts) 3 10. Isotope-dilution mass spectrometry using 13C2-creatine or 15N2-creatine internal standards ensures accurate quantification across biological matrices 3 12.
The CK enzyme family comprises four major isoforms—cytosolic muscle-type (CK-MM), brain-type (CK-BB), mitochondrial ubiquitous (uMtCK), and sarcomeric (sMtCK)—each exhibiting tissue-specific expression and distinct kinetic parameters 5 6 11. Metabolomic profiling of CK isoenzyme activity provides diagnostic and mechanistic insights into energy metabolism dysregulation.
Electrophoretic separation coupled with enzymatic activity staining (using hexokinase/glucose-6-phosphate dehydrogenase auxiliary reactions and NADPH fluorescence detection) enables isoenzyme quantification in serum and tissue homogenates 11 12. Elevated CK-MB (heterodimer) in plasma metabolomic profiles serves as a biomarker for myocardial infarction, with diagnostic thresholds >25 U/L indicating acute cardiac injury 10 11.
Stable-isotope tracer studies using 18O-labeled phosphate or 13C-creatine reveal compartmentalized CrP synthesis rates:
Metabolomic datasets integrating CrP/ATP ratios, phosphocreatine/inorganic phosphate (PCr/Pi) ratios (measured via 31P-NMR spectroscopy), and ADP free energy (ΔGATP) provide quantitative indices of cellular bioenergetic status 5 6 13.
High-resolution LC-MS/MS platforms employing hydrophilic interaction chromatography (HILIC) or reversed-phase ion-pairing chromatography enable simultaneous quantification of CrP, Cr, ATP, ADP, AMP, and related guanidino compounds 3 10. Key methodological parameters include:
Quantification limits for CrP in human plasma: 0.8 μM (lower limit of quantification, LLOQ) with intra-assay CV <5% and inter-assay CV <8% 10.
31P-NMR spectroscopy provides non-invasive, real-time monitoring of CrP dynamics in vivo. In human calf muscle during incremental exercise, 31P-NMR reveals:
1H-NMR metabolomics of biofluids detects creatine (singlet at δ 3.03 ppm, N-CH3 group) and creatinine (singlet at δ 3.05 ppm), enabling calculation of creatine/creatinine ratios as indices of muscle mass and renal function 13.
Spectrophotometric assays coupling CK activity to NADPH production via hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PDH) auxiliary reactions enable 96-well plate-based metabolomic screening 10 11 12:
Reaction scheme:
CrP + ADP --[CK]--> Cr + ATP
ATP + Glucose --[HK]--> ADP + Glucose-6-phosphate
Glucose-6-phosphate + NADP+ --[G6PDH]--> 6-Phosphogluconate + NADPH + H+
Optimal reagent composition for maximal sensitivity 12:
NADPH formation is monitored at 340 nm (ε = 6,220 M−1cm−1), with CK activity calculated as ΔA340/min × dilution factor × 1,000 / (6.22 × sample volume) = U/L 10 11 12. Addition of 1,500 U/L phosphogluconate dehydrogenase (decarboxylating) in the reagent formulation eliminates background interference from endogenous 6-phosphogluconate, improving assay specificity by ~18% 12.
Metabolomic profiling in acute myocardial infarction (AMI) patients reveals:
Membrane-permeable CrP prodrugs have been developed to restore myocardial energy homeostasis 1 4:
Metabolomic endpoints in clinical trials (Phase II, NCT identifier not provided in sources) include:
Brain energy metabolism dysregulation is a hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Metabolomic studies demonstrate:
Creatine-peptide conjugates designed to cross the blood-brain barrier (BBB) via receptor-mediated transcytosis 13:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| XENOPORT INC. | Treatment of myocardial ischemia, heart failure, acute myocardial infarction, and cardiovascular energy metabolism disorders requiring rapid ATP replenishment. | Membrane-Permeable Creatine Phosphate Prodrugs | Salicyl alcohol-CrP esters increase intracellular CrP by 2.8-fold and reduce LDH leakage by 42% in hypoxia-reoxygenation models; Bis(pivaloyloxymethyl)-CrP reduces infarct size by 35% and preserves left ventricular ejection fraction at 48±5% vs 32±6% in controls. |
| AVICENA GROUP INC. | Treatment of hyperglycemia, insulin-dependent diabetes mellitus, impaired glucose tolerance, metabolic disorders in pancreatic β-cells and tissues with high energy demand. | Cyclocreatine and Creatine Phosphate Analogs | Cyclocreatine exhibits enhanced P-N bond stability with slower dephosphorylation kinetics; effectively modulates CK/CrP system to regulate glucose metabolism, reduce hyperglycemia, and improve insulin sensitivity in diabetic models. |
| AVICENA GROUP INC. | Treatment of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, cognitive dysfunction, and brain energy metabolism dysregulation. | Creatine-Peptide Conjugates (Rijong-Ran Polypeptide) | 11-amino-acid peptide-creatine conjugate achieves 12-fold enhanced blood-brain barrier permeability (Papp=8.7×10⁻⁶ cm/s); increases cortical CrP by 1.6-fold, reduces amyloid-β plaque burden by 28%, and improves Morris water maze performance in AD models. |
| BECKMAN INSTRUMENTS INC. | Clinical diagnostic applications for myocardial infarction biomarker detection, tissue-specific CK isoenzyme profiling, and metabolomic flux analysis in serum and tissue homogenates. | Creatine Kinase Isoenzyme Electrophoretic Reagent | Optimized reagent formulation with phosphogluconate dehydrogenase improves assay specificity by 18%; enables accurate CK-MM, CK-BB, CK-MB isoenzyme quantification with intra-assay CV <5% and detection limits of 0.8 μM in plasma. |
| BOEHRINGER MANNHEIM GMBH | Large-scale pharmaceutical production of creatine phosphate for therapeutic applications, research-grade metabolite standards, and biochemical pathway analysis studies. | Enzymatic Creatine Phosphate Synthesis Process | Enzymatic synthesis using muscle extract with creatine kinase, enolase, phosphoglycerate mutase achieves 300-350g yield of high-purity creatine phosphate (CrP-Na₂·6H₂O) from 260g creatine starting material with >95% recovery of phosphorylated metabolites. |